Combined Metabolic Activators (CMAs) Improve Cognitive Functions without Altering Motor Scores in Parkinson's Disease

A new study assessing whether administration of a mixture of Combined Metabolic Activators (CMAs), including NAD+ precursor nicotinamide riboside (NR), could treat Parkinson’s disease patients, is ...